Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Heibei, PR China.
Future Oncol. 2022 Jun;18(18):2269-2288. doi: 10.2217/fon-2021-1087. Epub 2022 Apr 20.
To explore the prognostic value of the systemic inflammatory response index (SIRI) and peripheral blood T-cell subsets in patients with hepatocellular carcinoma (HCC) and the relationship between them. We treated 352 patients with HCC with sorafenib and/or immune checkpoint inhibitors (ICIs) and analyzed SIRI and peripheral blood T cells. SIRI was an independent prognostic factor for patients with HCC receiving systemic therapy. Patients with high SIRI and low baseline peripheral blood T-cell counts showed a poor response to ICIs. SIRI was significantly and negatively correlated with CD3, CD4 and CD8 T-cell counts. SIRI markers can be employed to noninvasively assess the presence of cancer-promoting inflammation in the tumor microenvironment and predict the efficacy of targeted therapy and immunotherapy.
探讨全身炎症反应指数（SIRI）和外周血 T 细胞亚群在肝细胞癌（HCC）患者中的预后价值及其之间的关系。我们用索拉非尼和/或免疫检查点抑制剂（ICIs）治疗了 352 例 HCC 患者，并对 SIRI 和外周血 T 细胞进行了分析。SIRI 是 HCC 患者接受系统治疗的独立预后因素。SIRI 高且基线外周血 T 细胞计数低的患者对 ICI 的反应较差。SIRI 与 CD3、CD4 和 CD8 T 细胞计数呈显著负相关。SIRI 标志物可用于无创评估肿瘤微环境中促癌炎症的存在，并预测靶向治疗和免疫治疗的疗效。
